仿製药市场规模 - 按药物类型（化疗、标靶治疗、免疫治疗、荷尔蒙治疗）、适应症（前列腺、肺、乳癌）、给药途径（口服、注射）、配销通路和全球预测，2024年至2032年

由于癌症盛行率上升、对具有成本效益的治疗方案的需求不断增加以及主要品牌肿瘤药物专利的到期，预计 2024 年至 2032 年仿製药市场规模将以 5.8% 的复合年增长率扩大。美国国家癌症研究所的资料显示，2024年，美国将诊断出约2,001,140例新癌症病例。

药品生产和监管审批的重大进步正在加速高品质仿製药的供应。新兴经济体医疗基础设施的扩张正在支持对负担得起的癌症治疗的高需求。医疗保健提供者和患者对仿製药的认识和接受程度不断提高，正在推动该产品的普及。

整个市场分为药物类型、适应症、给药途径、配销通路和地区。

根据药物类型，由于癌症盛行率增加、免疫治疗研究的进步以及对具有成本效益的治疗的高需求，免疫治疗药物领域的行业价值预计在2024 年至2032 年间将以强劲的复合年增长率增长。与传统疗法相比，疗效的提高和副作用的减少将增强免疫疗法的吸引力。关键免疫疗法药物专利的到期、政府对仿製药的支持政策以及人们对免疫治疗益处的认识不断增强也正在扩大该细分市场的成长。

就适应症而言，到2032 年，肺癌领域的仿製药肿瘤药物市场将获得巨大的吸引力。的进步。关键肺癌药物的专利到期将提高仿製药的可用性。新兴市场医疗保健服务的改善以及早期诊断和治疗意识的增强进一步推动了该细分市场的成长。

从区域来看，由于癌症的高盛行率、对负担得起的治疗的需求不断增长以及主要肿瘤药物的专利到期，欧洲仿製药市场预计从 2024 年到 2032 年将大幅成长。政府对仿製药生产的大力支持和有利的报销政策的存在正在加速药物的部署。医疗保健支出的增加、医疗保健服务取得的改善以及对非专利肿瘤药物的认识不断增强，正在推动区域市场的扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 癌症盛行率增加
    • 专利到期
    • 政府对仿製药的支持不断增加
    • 个人化治疗的需求不断增长
  • 产业陷阱与挑战
    • 保持一致的品质标准
• 成长潜力分析
• 管道分析
• 监管环境
• 报销场景
• 未来市场趋势
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类型，2021 - 2032

• 主要趋势
• 化疗药物
• 标靶治疗药物
• 免疫治疗药物
• 荷尔蒙治疗药物
• 其他药物种类

第 6 章：市场估计与预测：按指标划分，2021 - 2032 年

• 主要趋势
• 摄护腺癌
• 肺癌
• 乳癌
• 大肠直肠癌
• 白血病
• 其他适应症

第 7 章：市场估计与预测：按管理途径，22021 - 2032

• 主要趋势
• 口服
• 专题
• 可注射

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 9 章：市场估计与预测：按地区，202021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• AbbVie Inc.
• Apotex Inc.
• AstraZeneca
• Biocon Ltd.
• Gland Pharma Limited
• Incyte Corporation
• Lupin Pharmaceuticals, Inc.
• Mylan N.V.
• Natco Pharma Ltd.
• Novartis Pharmaceuticals Corporation
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Synthon Pharmaceuticals, Inc.
• Teva Pharmaceuticals
• Zydus Lifesciences Limited

Generic Oncology Drugs Market size is projected to expand at 5.8% CAGR from 2024 to 2032, led by the rising prevalence of cancer, increasing demand for cost-effective treatment options, and the expiration of patents for key branded oncology drugs. According to data from the National Cancer Institute, in 2024, approximately 2,001,140 new cases of cancer will be diagnosed in the U.S. The launch of government initiatives and support for generic drug production is also accelerating the product appeal.

Significant advancements in pharmaceutical manufacturing and regulatory approvals are accelerating the availability of high-quality generic oncology drugs. The expansion of healthcare infrastructure in emerging economies is supporting the high demand for affordable cancer treatments. The growing awareness and acceptance of generics among healthcare providers and patients is driving the product uptake.

The overall market is segregated into drug type, indication, route of administration, distribution channel, and region.

Based on drug type, the industry value from the immunotherapy drugs segment is estimated to rise at a robust CAGR between 2024 and 2032, due to increasing cancer prevalence, advancements in immunotherapy research, and high demand for cost-effective treatments. The improving efficacy and fewer side effects compared to traditional therapies will boost the appeal of immunotherapies. The expiration of patents of key immunotherapy drugs, supportive government policies for generics, and growing awareness of immunotherapy benefits are also expanding the segment growth.

With regards to indication, the generic oncology drugs market from the lung cancer segment will gain significant traction by 2032. This is owing to the high prevalence of lung cancer, increasing demand for affordable treatment options, and advancements in generic drug formulations. The expiring patents of key lung cancer drugs will boost generic availability. The improving healthcare access in emerging markets, and the growing awareness of early diagnosis and treatment are further boosting the segment growth.

Regionally, the Europe generic oncology drugs market is estimated to grow at a substantial rate from 2024 to 2032, led by the high prevalence of cancer, rising demand for affordable treatments, and expiration of patents of major oncology drugs. The strong government support for generic drug production and presence of favorable reimbursement policies are accelerating drug deployment. The increasing healthcare expenditure, improving access to healthcare services, and the growing awareness of generic oncology drugs are fueling the regional market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing cancer prevalence
    • 3.2.1.2 Patent expirations
    • 3.2.1.3 Growing government support towards generics
    • 3.2.1.4 Rising demand for personalized treatment
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Maintaining consistent quality standards
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Reimbursement scenario
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Chemotherapy drugs
• 5.3 Targeted therapy drugs
• 5.4 Immunotherapy drugs
• 5.5 Hormonal therapy drugs
• 5.6 Other drug types

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Prostate cancer
• 6.3 Lung cancer
• 6.4 Breast cancer
• 6.5 Colorectal cancer
• 6.6 Leukemia
• 6.7 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 22021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Topical
• 7.4 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 202021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 The Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Apotex Inc.
• 10.3 AstraZeneca
• 10.4 Biocon Ltd.
• 10.5 Gland Pharma Limited
• 10.6 Incyte Corporation
• 10.7 Lupin Pharmaceuticals, Inc.
• 10.8 Mylan N.V.
• 10.9 Natco Pharma Ltd.
• 10.10 Novartis Pharmaceuticals Corporation
• 10.11 Pfizer Inc.
• 10.12 Regeneron Pharmaceuticals Inc.
• 10.13 Synthon Pharmaceuticals, Inc.
• 10.14 Teva Pharmaceuticals
• 10.15 Zydus Lifesciences Limited